GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

UK's Cytospire draws in $83m for new T-cell engager platform

Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

CDR-Life Announces CDR209, a Novel T Cell Engager for Treatment of Axial Spondyloarthritis

Multi-specific Engagement Studies with World’s First Cell Avidity SPR Imaging Platform: the CellVysion

Multi-specific Engagement Studies with World’s First Cell Avidity SPR Imaging Platform: the CellVysion

2:50 pm - Wednesday 9th December 2026

Avidity driven binding on tumors with multispecific T-cell engagers
Tipping point measurements of cell capture under controlled shear conditions
KD analysis of biomolecular interactions on cell-receptors in solution
Label free determination of the number of specific receptors per cell

Speakers:

Richard Schasfoort

Richard Schasfoort

CSO

Vysens